Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

2 marca 2017 zaktualizowane przez: Pfizer

An Open-label, Phase 1/2 Study Of Inotuzumab Ozogamicin In Subjects With Relapsed Or Refractory Cd22-positive Acute Lymphocytic Leukemia

The Phase 1 portion of this study will assess the safety, tolerability and efficacy at increasing dose levels of inotuzumab ozogamicin in subjects with CD22-positive relapsed or refractory adult acute lymphocytic leukemia (ALL) in order to select the recommended phase 2 dose (RP2D) and schedule. The Phase 2 portion of the study will evaluate the efficacy of inotuzumab ozogamicin as measured by hematologic remission rate (CR + CRi) in patients in second or later salvage status.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

72

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

  • Stany Zjednoczone
    • California
      • Duarte, California, Stany Zjednoczone, 91010-3000
        • City of Hope National Medical Center
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Stanford Unversity Cancer Clinical Trials Office
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Stanford Unversity Hospital and Clinics, CTRU
      • Stanford, California, Stany Zjednoczone, 94305
        • Stanford Cancer Institute
      • Stanford, California, Stany Zjednoczone, 94305
        • Stanford University Hospital and Clinics
    • Illinois
      • Chicago, Illinois, Stany Zjednoczone, 60637
        • The University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Stany Zjednoczone, 02215
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, Stany Zjednoczone, 02215
        • Dana-Farber Cancer Institute
      • Boston, Massachusetts, Stany Zjednoczone, 02114
        • Massachusetts General Hospital (MGH)
      • Boston, Massachusetts, Stany Zjednoczone, 02115
        • Brigham and Women's Hospital (BWH)
    • Michigan
      • Detroit, Michigan, Stany Zjednoczone, 48201
        • Karmanos Cancer Institute
      • Farmington Hills, Michigan, Stany Zjednoczone, 48334
        • Karmanos Cancer Institute at Farmington Hills
    • Ohio
      • Cleveland, Ohio, Stany Zjednoczone, 44195
        • Cleveland Clinic
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • The University of Texas MD Anderson Cancer Center
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98109
        • Seattle Cancer Care Alliance

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Subjects with CD22-positive ALL with either refractory disease (i.e. disease progression or no response while receiving their most recent prior anti-cancer therapy), or relapsed disease (i.e. response to their most recent prior anti-cancer therapy with subsequent relapse). Subjects enrolled in the Phase 2 portion of the study must be due to receive salvage 2 or later therapy.
  • Subjects with Philadelphia chromosome-positive (Ph+) ALL must have failed standard treatment with at least one tyrosine kinase inhibitor.
  • Adequate renal and hepatic function, and negative pregnancy test for women of childbearing potential.

Exclusion Criteria:

  • Subjects with isolated extramedullary relapse or active central nervous system (CNS) leukemia.
  • Prior allogeneic hematopoietic stem cell transplant (HSCT) or other anti-CD22 immunotherapy within 4 months, or active graft versus host disease (GvHD) at study entry.
  • Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS).

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Inotuzumab Ozogamicin
Lek: Inotuzumab Ozogamicin

Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.

Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2.

Inne nazwy:
  • CMC-544

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants Reporting Dose Limiting Toxicities (DLTs) During the Phase 1 Dose-Finding Phase
Ramy czasowe: Cycle 1
DLT was any of the following in the first cycle & attributable to inotuzumab ozogamicin: any greater than or equal to (≥) Grade 4 non-hematologic toxicity except nausea/vomiting (if manageable with supportive care), alopecia, & toxicities secondary to neutropenia & sepsis; prolonged myelosuppression (absolute neutrophil count [ANC] less than [<] 500 per microliter [/µL] or platelet count <25,000/µL in bone marrow with <5 percent (%) blasts & no evidence of leukemia more than 45 days beyond the most recent dose of test article); any Grade 3 non-hematologic toxicity (excluding toxicities such as alopecia or those secondary to neutropenia & sepsis) not resolving to ≥ Grade 2 within 7 days of the most recent dose of test article or was clinically significant irrespective of duration; any ≥ Grade 3 elevation of alanine aminotransferase, aspartate aminotransferase or bilirubin lasting ≥7 days; any test article related toxicity resulting in permanent discontinuation of test article.
Cycle 1
Percentage of Participants With Preliminary Satisfactory Response (Complete Response [CR], CR With Incomplete Count Recovery [CRi], Partial Response [PR], or Resistant Disease [RD]) Indicating Disease Stability After First Dose During Phase 1 Dose-Finding
Ramy czasowe: From screening to progressive disease or another induction therapy started, up to approximately 2 years
CR was the disappearance of leukemia indicated by <5% marrow blasts and absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was as for CR except with ANC <1000/µL and/or platelets <100,000/µL. PR was an improved or no worsening of acute lymphocytic leukemia indicated by no peripheral blood blasts, and/or at least a 50% decrease in the marrow blast percentage, compared to pre-treatment value, and marrow blast percentage ≥5% and less than or equal to (≤)25% and/or C2 extramedullary disease status. RD occurred if a participant survived ≥7 days following completion of initial treatment course and had persistent leukemia in the most recent peripheral blood smear or bone marrow and/or persistent disease involvement at any extramedullary site after completion of therapy.
From screening to progressive disease or another induction therapy started, up to approximately 2 years
Percentage of Participants With CR or CRi During Phase 2
Ramy czasowe: From screening to progressive disease or another induction therapy started, up to approximately 2 years
CR was defined as a disappearance of leukemia as indicated by <5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC <1000/µL and/or platelets <100,000/µL.
From screening to progressive disease or another induction therapy started, up to approximately 2 years
Percentage of Participants With CR, CRi or PR During the Phase 1 Expansion Phase
Ramy czasowe: From screening to progressive disease or another induction therapy started, up to approximately 2 years
CR was defined as a disappearance of leukemia as indicated by <5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC <1000/µL and/or platelets <100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.
From screening to progressive disease or another induction therapy started, up to approximately 2 years

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With CR, CRi or PR in Phase 2
Ramy czasowe: From screening to progressive disease or another induction therapy started, up to approximately 2 years
CR was defined as a disappearance of leukemia as indicated by <5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC <1000/µL and/or platelets <100,000/µL. PR was defined as an improved or no worsening of acute lymphocytic leukemia as indicated by no peripheral blood blasts, and either or both of the following: at least a 50% decrease in the marrow blast percentage, compared to the pre-treatment value, and marrow blast percentage ≥5% and ≤25% and/or C2 extramedullary disease status.
From screening to progressive disease or another induction therapy started, up to approximately 2 years
Number of Participants With Minimal Residual Disease (MRD) Negativity in Participants Achieving CR and CRi
Ramy czasowe: From screening to progressive disease or another induction therapy started, up to approximately 2 years
MRD negativity was defined as <0.01% mononuclear cells.
From screening to progressive disease or another induction therapy started, up to approximately 2 years
Percentage of Participants With CR or CRi by Cytogenetic Category
Ramy czasowe: From screening to progressive disease or another induction therapy started, up to approximately 2 years
CR was defined as a disappearance of leukemia as indicated by <5% marrow blasts and the absence of peripheral blood leukemic blasts, with recovery of hematopoiesis defined by ANC ≥1000/µL and platelets ≥100,000/µL. C1 extramedullary disease status was required. CRi was defined as CR except with ANC <1000/µL and/or platelets <100,000/µL.
From screening to progressive disease or another induction therapy started, up to approximately 2 years
Percentage of Participants Who Had a Post-Treatment Stem-Cell Transplant (SCT)
Ramy czasowe: Up to approximately 2 years from first dose
Post-treatment SCT rate was defined as the percentage of participants who underwent SCT following treatment with inotuzumab ozogamicin.
Up to approximately 2 years from first dose
Progression Free Survival (PFS)
Ramy czasowe: Up to approximately 2 years from first dose
PFS was defined as the time from Cycle 1 Day 1 to first documentation of PFS event (earliest date of objective progression [PD], treatment discontinuation due to global deterioration of health status, subsequent induction or transplant after best response of PR or resistant disease, relapse after CR or CRi, or death due to any cause). Participants last known to be 1) alive and 2) without a PFS event, were censored at the date of the last disease assessment that verified lack of event.
Up to approximately 2 years from first dose
Duration of Remission (DoR1) for Participants Who Achieved CR or CRi
Ramy czasowe: Up to approximately 2 years from first dose
DoR1 was defined for participants who responded as the time from the date of first documentation of Complete Hematologic Response (CR or CRi) to the date of the first documentation of relapse after CR or CRi, treatment discontinuation due to global deterioration of health status) or to death due to any cause. Participants last known to be 1) alive and 2) without a DoR1 event, were censored at the date of the last disease assessment that verified lack of event.
Up to approximately 2 years from first dose
Duration of Response (DoR) for Participants Who Achieved CR/CRi or PR
Ramy czasowe: Up to approximately 2 years from first dose
DoR was defined for participants who respond as the time from the date of first documentation of Hematologic Response (CR, CRi, or PR) to the date of the first documentation of DoR event (earliest date of PD, treatment discontinuation due to global deterioration of health status, first induction therapy or transplant after PR, relapse after CR or CRi or death due to any cause). Participants last known to be 1) alive and 2) without a DoR event, were censored at the date of the last disease assessment that verified lack of event.
Up to approximately 2 years from first dose
Overall Survival (OS)
Ramy czasowe: Up to approximately 2 years from first dose
OS was defined as the time from Cycle 1 Day 1 to date of death due to any cause. If death was not documented, censoring occurred at the date at which the participant was last known to be alive.
Up to approximately 2 years from first dose
Time to Remission for Participants Who Achieved CR or CRi
Ramy czasowe: Up to approximately 2 years from first dose
Time to remission was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic remission (CR or CRi) in participants achieving remission during study therapy.
Up to approximately 2 years from first dose
Time to Response for Participants Who Achieved CR/CRi or PR
Ramy czasowe: Up to approximately 2 years from first dose
Time to response was defined as the time from the date of first dose of study drug to the date of first documentation of hematologic response (CR, CRi, or PR).
Up to approximately 2 years from first dose
Time to MRD Negativity for Participants Who Achieved CR or CRi
Ramy czasowe: Screening, Day 21 of Cycles 1 to 6 and up to 4 to 6 weeks after the last dose (up to 34 weeks)
Time to MRD negativity was defined as the time from the date of first dose of study drug to the date of first documentation of MRD negativity.
Screening, Day 21 of Cycles 1 to 6 and up to 4 to 6 weeks after the last dose (up to 34 weeks)
Duration of Follow-Up
Ramy czasowe: From first dose up to approximately 2 years
Duration of follow-up was defined as the time from the date of first dose of study drug to the date of last contact for participants known to be alive.
From first dose up to approximately 2 years
Percentage of Cluster of Differentiation-22 Positive (CD22+) Leukemic Blasts in Abnormal B Cells in Blood by Visit
Ramy czasowe: Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4
CD22+ leukemic blasts assessed in abnormal B cells from blood (data from central laboratories only).
Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4
Percentage of CD22+ Leukemic Blasts in Abnormal B Cells in Bone Marrow by Visit
Ramy czasowe: Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4
CD22+ leukemic blasts assessed in abnormal B cells from bone marrow (data from central laboratories only).
Pre-dose on Days 1 and 15 of Cycles 1 and 2, and Day 1 of Cycle 4
Messenger Ribonucleic Acid (mRNA) Gene Expression
Ramy czasowe: Predose and postdose on Days 1 and 15 of Cycle 1
Optional blood samples for pharmacogenomic parameters were collected during Cycle 1 prior to the start of the inotuzumab ozogamicin infusion (0 hours) and 1 hour post-dose (original Final Protocol and Protocol Amendments 1 and 2) or 3 hours post-dose (Protocol Amendments 3 and 4) on Day 1 and Day 15 from those participants who provided consent. Gene expression analysis of samples collected pre- and post-dosing was performed using 96-gene TaqMan® low density array cards to examine the concordance between clinical outcome and expression of genes such as those involved in DNA damage response, apoptosis, B-cell antigen expression, glutathione metabolism, drug transport and the phosphoinositide 3-kinase/mammalian target of rapamycin pathway. Expression for each gene was reported as a normalized value, 2^-change in (∆) threshold cycle (Ct), where ∆Ct is Ct^target gene minus Ct^reference genes, averaged.
Predose and postdose on Days 1 and 15 of Cycle 1

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Pfizer

Współpracownicy

UCB Pharma

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Przydatne linki

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów

1 sierpnia 2011

Zakończenie podstawowe (Rzeczywisty)

1 sierpnia 2014

Ukończenie studiów (Rzeczywisty)

1 stycznia 2016

Daty rejestracji na studia

Pierwszy przesłany

11 maja 2011

Pierwszy przesłany, który spełnia kryteria kontroli jakości

27 maja 2011

Pierwszy wysłany (Oszacować)

1 czerwca 2011

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 kwietnia 2017

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

2 marca 2017

Ostatnia weryfikacja

1 marca 2017

Więcej informacji

Terminy związane z tym badaniem

Słowa kluczowe

Dodatkowe istotne warunki MeSH

Inne numery identyfikacyjne badania

  • B1931010
  • 3129K6-1106 (Inny identyfikator: Alias Study Number)

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Ostra białaczka limfocytowa

Badania kliniczne na Inotuzumab Ozogamicin

Wyszukaj podobne próby

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

CROs by country

CROs in Angola

Warunki

Rzadkie choroby

Interwencje lekowe

Suplementy diety

Sponsor / Współpracownicy

Lokalizacje

3
Subskrybuj